Behind the headlines

30 November 2018
Autumn 2018
AMD Glaucoma Low vision

Dr David Robert Grimes looks at the eye health issues that are making the news.

/COO/media/Media/Acuity/Autumn 2018/Behind-headlines-avastin-CREDIT-Alamy-600x400_1.jpg

NHS to save millions on AMD treatment

A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.

In September, the High Court ruled against the drug giants. 

Sign in to continue

Forgotten password?
Register

Not already a member of the College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

benefits of membership

Related further reading

Elderly eyes and domiciliary eye care: managing the challenges, improving care

This article provides high-level summary information on the changing demographics of the ageing population and associated disability.

Low vision

Supplements and eye health

Reviewing the evidence for the role of supplements in eye health, particularly cataract and age-related macular degeneration (AMD).

AMD Public health

Management of open-angle glaucoma after the LIGHT trial: what is the role of hospital optometri...

This article outlines the laser treatment modalities for glaucoma and ocular hypertension.

Glaucoma